Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Extension Study of Ataluren (PTC124) in Patients with Nonsense Mutation Cystic Fibrosis
2014-005355-83Phase 3Terminated
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ataluren in cystic fibrosis (CF), sponsored by PTC Therapeutics, Inc.. Started Aug 2015; status: terminated.
02
Drugs
ataluren
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2014-005355-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005355-83.